Zhu Yingchun, Mi Yunfeng, Wang Zheyang, Jia Xuewen, Jin Zhanping
Department of Orthopedics, Ningbo First Hospital, Ningbo, Zhejiang 315000, P.R. China.
Oncol Lett. 2019 Jan;17(1):456-461. doi: 10.3892/ol.2018.9615. Epub 2018 Oct 24.
Osteosarcoma is the most frequent malignant bone tumor in children and adolescents. Norcantharidin (NCTD) is a purified component from blister beetles and has been identified to exert antitumor effects in a variety of cancer types. However, the antitumor effect of NCTD in osteosarcoma remains to be elucidated. In the current study, it was first demonstrated that NCTD inhibited proliferation and induced G2/M-phase arrest and cell apoptosis in human osteosarcoma cells. Furthermore, NCTD significantly decreased the phosphorylation of Akt and the mammalian target of rapamycin in human osteosarcoma cells. These results suggest that NCTD is a promising candidate for the treatment of osteosarcoma patients in the future.
骨肉瘤是儿童和青少年中最常见的恶性骨肿瘤。去甲斑蝥素(NCTD)是一种从斑蝥中提纯的成分,已被证实对多种癌症类型具有抗肿瘤作用。然而,NCTD在骨肉瘤中的抗肿瘤作用仍有待阐明。在本研究中,首次证明NCTD可抑制人骨肉瘤细胞的增殖,诱导G2/M期阻滞和细胞凋亡。此外,NCTD显著降低人骨肉瘤细胞中Akt和雷帕霉素哺乳动物靶点的磷酸化水平。这些结果表明,NCTD有望成为未来治疗骨肉瘤患者的候选药物。